alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
* Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 97-41118

Conference Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

RAMIRO MANUEL BAZALDUA-LANDEROS,

Defendant-Appellant.

- - - - - - - - - -

Appeal from the United States District Court

for the Southern District of Texas

USDC No. M-97-CR-62-1

- - - - - - - - - -

August 19, 1998

Before KING, HIGGINBOTHAM, and JONES, Circuit Judges. 

PER CURIAM:*

Court-appointed counsel for Ramiro Manuel Bazaldua-Landeros

has filed a brief as required by Anders v. California, 386 U.S.

738 (1967). Our independent review of the brief, BazalduaLanderos’s response, and the record discloses no nonfrivolous

issue. Accordingly, counsel is excused from further

responsibilities herein, and the APPEAL IS DISMISSED. See 5TH

CIR. R. 42.2.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE 
STATEMENTS OF FINANCIAL CONDITION AND STATEMENTS OF INCOME FOUND ON PAGES 3 AND 
4 OF THE PARTNERSHIP'S FORM 10-Q FOR THE YEAR-TO-DATE, AND IS QUALIFIED IN ITS 
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK>                         0000814562
<NAME>                        OPPENHEIMER CAPITAL, L.P.
<MULTIPLIER>                  1,000                                     
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              APR-30-1996
<PERIOD-START>                                 MAY-01-1996
<PERIOD-END>                                   OCT-31-1996
<CASH>                                                  55
<SECURITIES>                                             0
<RECEIVABLES>                                            0
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                    11,483<F1>
<PP&E>                                                   0
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                     112,550<F2>
<CURRENT-LIABILITIES>                               11,642
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                                 0
<OTHER-SE>                                         100,908<F3>
<TOTAL-LIABILITY-AND-EQUITY>                       112,550
<SALES>                                                  0
<TOTAL-REVENUES>                                    25,588
<CGS>                                                    0
<TOTAL-COSTS>                                            0
<OTHER-EXPENSES>                                     1,371
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                     24,217
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                 24,217
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                        24,217
<EPS-PRIMARY>                                         1.56
<EPS-DILUTED>                                         1.56
<FN>
<F1> CURRENT ASSETS IS COMPRISED OF CASH ($55), DISTRIBUTION RECEIVABLE 
     ($10,890), AND INTEREST RECEIVABLE ($538)
<F2> TOTAL ASSETS INCLUDE CURRENT ASSETS PLUS INVESTMENT IN OPPENHEIMER CAPITAL
     ($28,153), A NON-TRADE NOTE RECEIVABLE ($32,193), GOODWILL ($40,589) AND
     OTHER ASSETS ($132)
<F3> OTHER SHAREHOLDERS EQUITY IS COMPROSED OF GENERAL PARTNER'S CAPITAL
     ($1,023) AND LIMITED PARTNERS' CAPITAL ($99,885)
</FN>

        


</TABLE>
Exhibit 32.1

                           SECTION 1350 CERTIFICATION

In connection with the quarterly report of InZon Corporation
(formerly W-J International, Ltd.) ("Company") on Form 10-QSB for the
quarter ended March 31, 2005 as filed with the Securities and Exchange
Commission ("Report"), the undersigned, in the capacities and on the
dated indicated below, hereby certify pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) that to their
knowledge:

1.	The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.


Dated: August 18, 2005              By: /s/ David F. Levy
                                        ------------------
		 		    	David F. Levy
                                        Chief Executive Officer


Dated: August 18, 2005              By: /s/ Richard Dea
                                        ------------------
		 		    	Richard Dea
                                        Chief Financial Officer
### THE THIRTEENTH COURT OF APPEALS

13

- 16

- 00058

- CR

MICHAEL DEWAYNE DIAZ

v. THE STATE OF TEXAS

On Appeal from the 130th District Court of Matagorda County , Texas

Trial Cause No. 15

- 250

JUDGMENT THE THIRTEENTH COURT OF APPEALS, having considered this ca use on appeal, concludes the appeal should be dismissed. The Court orders the appeal

DISMISSED in accordance with its opinion

. We further order this decision certified below for observance.
May 19, 2016
DISTRICT COURT OF APPEAL OF FLORIDA

SECOND DISTRICT

CITY OF TAMPA,

Appellant,

v.

TAMPA POLICE BENEVOLENT ASSOCIATION, INC.,

Appellee.

No. 2D22-2630

September 27, 2023

Appeal from the Public Employees Relations Commission.

Thomas M. Gonzalez and Natasha Khoyi of GrayRobinson, P.A., Tampa, 

for Appellant.

Luke Newman of Luke Newman, P.A., Tallahassee, for Appellee.

PER CURIAM.

Affirmed. 

MORRIS, SMITH, and LABRIT, JJ., Concur.

Opinion subject to revision prior to official publication.
#### § 82.1331 D&C Red No. 31.

The color additive D&C Red No. 31 shall conform in identity and specifications to the requirements of § 74.1331(a)(1) and (b) of this chapter. D&C Red No. 31 is restricted to use in externally applied drugs and cosmetics.
I 

118TH CONGRESS 

2D SESSION H. R. 7426 

To amend part A of title IV of the Social Security Act to target funds 

to families in need. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 20, 2024 

Mr. SMITH of Nebraska introduced the following bill; which was referred to 

the Committee on Ways and Means 

A BILL 

To amend part A of title IV of the Social Security Act 

to target funds to families in need. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Targeting TANF to 

5 Families in Need Act’’. 

6 SEC. 2. TARGETING FUNDS TO FAMILIES IN NEED. 

7 (a) IN GENERAL.—Section 404 of the Social Security 

8 Act (42 U.S.C. 604) is amended by adding at the end the 

9 following: 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7426 IH

1 ‘‘(l) ESTABLISHING A THRESHOLD FOR FAMILIES IN

2 NEED.—A State to which a grant is made under section 

3 403(a)(1) shall use the grant only to provide assistance 

4 or services to a family whose income is less than twice 

5 the poverty guidelines updated periodically in the Federal 

6 Register under section 673(2) of the Omnibus Budget 

7 Reconciliation Act of 1981 (42 U.S.C. 9902(2)).’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) shall take effect on October 1, 2025. 

10 SEC. 3. TWO-YEAR REAUTHORIZATION OF THE TEMPORARY 

11 ASSISTANCE FOR NEEDY FAMILIES PRO12 GRAM. 

13 Activities authorized by part A of title IV (other than 

14 under section 403(c) or 418) and section 1108(b) of the 

15 Social Security Act shall continue through September 30, 

16 2026, in the manner authorized for fiscal year 2023, and 

17 out of any money in the Treasury of the United States 

18 not otherwise appropriated, there are hereby appropriated 

19 such sums as may be necessary for such purpose. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.169 Grape color extract. ( a ) *Identity.* ( 1 ) The color additive grape color extract is an aqueous solution of anthocyanin grape pigments made from Concord grapes or a dehydrated water soluble powder prepared from the aqueous solution. The aqueous solution is prepared by extracting the pigments from precipitated lees produced during the storage of Concord grape juice. It contains the common components of grape juice, namely anthocyanins, tartrates, malates, sugars, and minerals, etc., but not in the same proportion as found in grape juice. The dehydrated water soluble powder is prepared by spray drying the aqueous solution containing added malto-dextrin.
( 2 ) Color additive mixtures for food use made with grape color extract may contain only those diluents listed in this subpart as safe and suitable in color additive mixtures for coloring foods.
( b ) *Specifications.* Grape color extract shall conform to the following specifications: Pesticide residues, not more than permitted in or on grapes by regulations promulgated under section 408 of the Federal Food, Drug, and Cosmetic Act. Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 1 part per million.
( c ) *Uses and restrictions.* Grape color extract may be safely used for the coloring of nonbeverage food, except that it may not be used to color foods for which standards of identity have been promulgated under section 401 of the act, unless the use of added color is authorized by such standards.
( d ) *Labeling.* The color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall bear, in addition to the other information required by the act, labeling in accordance with the provisions of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches are exempt from the certification requirements of section 721(c) of the Act.
[46 FR 47532, Sept. 29, 1981]
§ 520.1447 Milbemycin oxime, lufenuron, and praziquantel tablets. ( a ) *Specifications.* Each tablet contains: ( 1 ) 2.3 milligrams (mg) milbemycin oxime, 46 mg lufenuron, and 22.8 mg praziquantel;
( 2 ) 5.75 mg milbemycin oxime, 115 mg lufenuron, and 57 mg praziquantel;
( 3 ) 11.5 mg milbemycin oxime, 230 mg lufenuron, and 114 mg praziquantel; or
( 4 ) 23 mg milbemycin oxime, 460 mg lufenuron, and 228 mg praziquantel.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) [Reserved]
( d ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* 0.5 mg milbemycin oxime, 10 mg lufenuron, and 5 mg of praziquantel per kilogram of body weight, once a month.
( ii ) *Indications for use.* For the prevention of heartworm disease caused by *Dirofilaria immitis;* for the prevention and control of flea populations (*Ctenocephalides felis*); and for the treatment and control of adult roundworm (*Toxocara canis, Toxascaris leonina*), adult hookworm (*Ancylostoma caninum*), adult whipworm (*Trichuris vulpis*), and adult tapeworm (*Dipylidium caninum, Taenia pisiformis,* *Echinococcus multilocularis,* and *E. granulosus*) infections in dogs and puppies 2 pounds of body weight or greater and 6 weeks of age and older.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) [Reserved]
[77 FR 4225, Jan. 27, 2012, as amended at 80 FR 18776, Apr. 8, 2015; 83 FR 13635, Mar. 30, 2018; 86 FR 13184, Mar. 8, 2021]
RECEIVED \H

The Court of Aopeals

Sixth District

JUL 0 2 ZQft

D; jtk

Todd Turner

Wood Cou

PO BoxstfOl

Quitman, TX 75783

istrict Clerk

The TURNER Firm

PO Box 100696

Fort Worth, Texas 76185

todd@theturnerfirm.net

June 20, 2015

Re: Steven Brown v. Tim Jackson Construction Co., Inc. et al.

^pellant'Gdme~'Nby06n5^m(i2'3^V=:====:^^

Trial Court Cause No. 2013-116

Dear Court Clerk:

My office address and email have changed so please make sure your records accurately

reflect same as I have recently received a document from months ago:

The Turner Firm

POBox 100696

Fort Worth, Texas 76185

Todd@theturnerfirm.net

Enclosed is the Clerk's Record fee of $233.00. Please contact the appellate court as soon

as possible to notify them ofthis payment.

If you have any questions, please do not hesitate to contact me.

cc:

i/^ Sixth Court ofAppeals
§ 516.29 Termination of MUMS-drug designation. ( a ) The sponsor of a MUMS-designated drug must notify FDA of any decision to discontinue active pursuit of conditional approval or approval of such MUMS drug. FDA must terminate the designation upon such notification.
( b ) A conditionally-approved or approved MUMS-designated drug sponsor must notify FDA at least 1 year before it intends to discontinue the manufacture of such MUMS drug. FDA must terminate designation upon such notification.
( c ) MUMS designation shall terminate upon the expiration of any applicable period of exclusive marketing rights under this subpart.
( d ) FDA may terminate designation if it independently determines that the sponsor is not actively pursuing conditional approval or approval with due diligence. At a minimum, due diligence must be demonstrated by: ( 1 ) Submission of annual progress reports in a timely manner in accordance with § 516.30 that demonstrate that the sponsor is progressing in accordance with the drug development plan submitted to the agency under § 516.20 and
( 2 ) Compliance with all applicable requirements of part 511 of this chapter.
( e ) Designation of a conditionally approved or approved MUMS-designated drug and the associated exclusive marketing rights may be terminated if the sponsor is unable to provide sufficient quantities of the drug to meet the needs for which it is designated.
( f ) FDA may also terminate MUMS-drug designation for any drug if the agency finds that: ( 1 ) The request for designation contained an untrue statement of material fact; or
( 2 ) The request for designation omitted material information required by this subpart; or
( 3 ) FDA subsequently finds that the drug in fact had not been eligible for MUMS-drug designation at the time of submission of the request;
( 4 ) The same drug, in the same dosage form, for the same intended use becomes conditionally approved or approved for another sponsor; or
( 5 ) FDA withdraws the conditional approval or approval of the application for the new animal drug.
( g ) For a conditionally approved or approved drug, termination of MUMS-drug designation also terminates the sponsor's exclusive marketing rights for the drug but does not withdraw the conditional approval or approval of the drug's application.
( h ) Where a drug has been MUMS-designated for a minor use in a major species, its designation will not be terminated on the grounds that the number of animals to which the drug could potentially be administered on an annual basis for the treatment, control, or prevention of the disease or condition for which the drug is being developed, including animals administered the drug as part of herd or flock treatment, subsequently increases.
( i ) When a MUMS-drug designation is terminated, FDA will notify the sponsor in writing and will give public notice of the termination of the MUMS-drug designation.
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 741 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                H. R. 741

   To amend the Fair Labor Standards Act of 1938 to provide that an 
   employee's ``regular rate'' for purposes of calculating overtime 
   compensation will not be affected by certain additional payments.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 2, 2023

 Mr. Calvert introduced the following bill; which was referred to the 
                Committee on Education and the Workforce

_______________________________________________________________________

                                 A BILL

 
   To amend the Fair Labor Standards Act of 1938 to provide that an 
   employee's ``regular rate'' for purposes of calculating overtime 
   compensation will not be affected by certain additional payments.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Employee Bonus Protection Act''.

SEC. 2. REGULAR RATE FOR OVERTIME PURPOSES.

    Section 7(e) of the Fair Labor Standards Act of 1938 is amended--
            (1) by inserting before the semicolon at the end of 
        paragraph (3) the following: ``; or (d) the payments are made 
        to reward an employee or group of employees for meeting or 
        exceeding the productivity, quality, efficiency, or sales goals 
        as specified in a gainsharing plan, incentive bonus plan, 
        commission plan, or performance contingent bonus plan''; and
            (2) by adding at the end the following:
``A plan described in clause (d) of paragraph (3) shall be in writing 
and made available to employees, provided that the amount of the 
payments to be made under the plan be based upon a formula that is 
stated in the plan, and be established and maintained in good faith for 
the purpose of distributing to employees additional remuneration over 
and above the wages and salaries that are not dependent upon the 
existence of such plan or payments made pursuant to such plan.''.
                                 <all>
```
§ 507.27 Holding and distribution. ( a ) Animal food held for distribution must be held under conditions that will protect against contamination and minimize deterioration, including the following: ( 1 ) Containers used to hold animal food before distribution must be designed, constructed of appropriate material, cleaned as necessary, and maintained to protect against the contamination of animal food; and
( 2 ) Animal food held for distribution must be held in a way that protects against contamination from sources such as trash.
( b ) The labeling for the animal food ready for distribution must contain, when applicable, information and instructions for safely using the animal food for the intended animal species.
( c ) Shipping containers (*e.g.,* totes, drums, and tubs) and bulk vehicles used to distribute animal food must be examined prior to use to protect against the contamination of animal food from the container or vehicle when the facility is responsible for transporting the animal food itself or arranges with a third party to transport the animal food.
( d ) Animal food returned from distribution must be assessed for animal food safety to determine the appropriate disposition. Returned animal food must be identified as such and segregated until assessed.
( e ) Unpackaged or bulk animal food must be held in a manner that does not result in unsafe cross contamination with other animal food.
[80 FR 56337, Sept. 17, 2015, as amended at 81 FR 3717, Jan. 22, 2016]
#### § 740.19 Suntanning preparations.

The labeling of suntanning preparations that do not contain a sunscreen ingredient must display the following warning: “Warning—This product does not contain a sunscreen and does not protect against sunburn. Repeated exposure of unprotected skin while tanning may increase the risk of skin aging, skin cancer, and other harmful effects to the skin even if you do not burn.” For purposes of this section, the term “suntanning preparations” includes gels, creams, liquids, and other topical products that are intended to provide cosmetic effects on the skin while tanning through exposure to UV radiation (e.g., moisturizing or conditioning products), or to give the appearance of a tan by imparting color to the skin through the application of approved color additives (e.g., dihydroxyacetone) without the need for exposure to UV radiation. The term “suntanning preparations” does not include products intended to provide sun protection or otherwise intended to affect the structure or any function of the body.

[64 FR 27693, May 21, 1999]
§ 524.1484k Neomycin and prednisolone suspension. ( a ) *Specifications.* Each milliliter of suspension contains 2.5 milligrams of prednisolone acetate and 5 milligrams of neomycin sulfate equivalent to 3.5 milligrams of neomycin base.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* For beginning treatment of acute ocular inflammations place 1 or 2 drops in the conjunctival sac 3 to 6 times during a 24 hour period. When improvement occurs, reduce the dosage to 1 drop 2 to 4 times daily. For otitis externa, place 2 to 6 drops in the external ear canal 2 or 3 times daily.
( 2 ) *Indications for use.* For the treatment of treating infectious, allergic and traumatic keratitis and conjunctivitis, acute otitis externa, and chronic otitis externa.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 10971, Feb. 27, 2014]
**EPRI Species List with Life History Information for Equivalent Adult and Production Foregone Analysis**

**Marine species** 1. American shad 2. Blueback herring 3. Bay Anchovy 4. Atlantic menhaden 5. Gulf menhaden 6. Atlantic silverside 7. Striped bass 8. White perch 9. Atlanticcroaker 10. Spot 11. Weakfish 12. Red drum 13. Winter flounder 14. White croaker 15. Blue crab 16. White, pink, and brown shrimp 17. Pacific sardine 18. Cunner 19.Tautog 20. Naked goby 21. Hogchoker 22.Three

-spine stickleback 23. Alewife 24. Cutlassfish 25. Mojarra 26. Silver perch 27. Silver hake Top entrained marinespecies per EPRI I&E Survey (not ranked; excludes Hawaii and Puerto Rico) 1. Gobies 2. Northernanchovy 3. Cunner 4. Bay anchovy 5. Atlantic menhaden 6. Tautog 7. White perch 8. White, brown and pink shrimp

Top impinged marine species per EPRI I&E Survey (not ranked; excludes Hawaii and Puerto Rico) 1. Queenfish 2. Northern anchovy 3. Red rock shrimp 4. Round stingray 5. Topsmelt 6. Atlantic menhaden 7. Atlantic silverside 8. Winter flounder 9. Blue crab 10. Atlantic croaker 11. White, brown and pink shrimp 12. Hogchoker**Freshwater species**

1. Great Lakes alewife 2. Channel catfish 3. Freshwater drum 4. White bass 5. Gizzard shad 6. Threadfin shad 7. Emerald shiner 8. Rainbow smelt 9. Yellow perch 10. Black crappie 11. Round goby 12. Smallmouth bass 13. Bluegill 14. Shovelnose sturgeon 15. Bigmouth buffalo 16. Shorthead redhorse 17. Brown bullhead 18. Slimy sculpin 19. Burbot 20. Lake whitefish 21. logperch 22. Walleye 23. Great Lakes white perch Top entrained freshwater species per EPRI I&E Survey (not ranked): 1. Alewife 2. Gizzard shad 3. Cyprinids 4. Round goby 5. Yellow perch 6. Brook silverside 7. Catostomids (suckers) 8. Lepomis species (bluegill)

Top impinged freshwater species per EPRI I&E Survey (not ranked): 1. Gizzard shad 2. Threadfin shad 3. Alewife 4. Bluegill 5. Channel catfish 6. Emerald shiner 7. Yellow perch 8. Threespine stickleback 9. White crappie 10. Largemouth bass 11. Freshwater drum 12. Inland silverside